CAPRICOR THERAPEUTICS, INC.: TANG CAPITAL MANAGEMENT LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Tang Capital Management LLC amended its Schedule 13G filing for Capricor Therapeutics Inc., updating its disclosed stake in the company with the SEC under accession number 0001214659-26-014413. The amendment signals a change in the investment firm's position in the clinical-stage biotech, which is developing cell and exosome-based therapies. Schedule 13G filings are required of passive investors holding above 5% of a company's shares, so the update indicates Tang Capital's ownership has shifted since its prior disclosure. Investors will watch for further detail on the size and direction of the stake change, which can signal confidence or reduced exposure in the thinly traded biotech.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Capricor Therapeutics, Inc., Tang Capital Management LLC